Yousif Capital Management Trims Johnson & Johnson Stake

Institutional investor reduces position in pharmaceutical giant by 3%

Apr. 12, 2026 at 11:56am

Got story updates? Submit your updates here. ›

A high-contrast, macro-level view of the mechanical components and moving parts that make up the infrastructure of the banking system, conveying a sense of the industry's scale and complexity.The complex inner workings of the financial industry, captured in a dramatic, high-resolution close-up.New Brunswick Today

Yousif Capital Management LLC, a financial services firm, decreased its position in shares of Johnson & Johnson (NYSE: JNJ) by 3% in the fourth quarter, according to a recent SEC filing. The fund now owns 310,460 shares of the company's stock, valued at $67.7 million.

Why it matters

Johnson & Johnson is a bellwether stock in the healthcare sector, and changes to major institutional investors' holdings can signal broader market trends or shifts in sentiment around the company. This move by Yousif Capital Management is a relatively small reduction, but it may indicate some caution or profit-taking around J&J's recent stock price gains.

The details

According to the 13F filing, Yousif Capital Management sold 9,689 shares of Johnson & Johnson during the fourth quarter. The fund now owns a $67.7 million stake in the pharmaceutical giant, comprising approximately 0.7% of its total investment portfolio.

  • The transaction occurred in the fourth quarter of 2025.
  • Yousif Capital Management filed the 13F report disclosing the sale on April 12, 2026.

The players

Yousif Capital Management LLC

A financial services firm that manages investments for institutional and individual clients.

Johnson & Johnson

A multinational pharmaceutical and medical devices company headquartered in New Brunswick, New Jersey.

Got photos? Submit your photos here. ›

What they’re saying

“We must remain vigilant in our portfolio management to ensure we are properly positioned for the evolving market conditions.”

— John Yousif, Chief Investment Officer, Yousif Capital Management

What’s next

Investors will be closely watching Johnson & Johnson's upcoming Q1 earnings report for any signs of headwinds or tailwinds that could impact the stock price and institutional investor sentiment.

The takeaway

This modest reduction in Yousif Capital's Johnson & Johnson holdings suggests some caution, but the company remains a core position in the fund's portfolio. Analysts will continue to monitor institutional activity around this healthcare bellwether as the market navigates shifting economic conditions.